Tenosynovial Giant Cell Tumor
NCI Definition: A tumor usually arising in the synovium of joints, bursa or tendon sheath. It is characterized by the presence of mononuclear cells, multinucleated osteoclast-like giant cells, hemosiderin-laden macrophages, foam cells, and an inflammatory infiltrate. According to the growth pattern, it is classified as localized or diffuse. 
Tenosynovial giant cell tumors most frequently harbor alterations in NOTCH1, TP53, PDGFRA, NOTCH3, and MECOM .
NOTCH1 Mutation, NOTCH1 Missense, TP53 c.217-c.1178 Missense, TP53 R175H, and TP53 Mutation are the most common alterations in tenosynovial giant cell tumor .
There are 4 clinical trials for tenosynovial giant cell tumor, of which 4 are open and 0 are completed or closed. Of the trials that contain tenosynovial giant cell tumor as an inclusion criterion, 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 4 (1 open).
Pexidartinib, dcc-3014, and pd-0360324 are the most common interventions in tenosynovial giant cell tumor clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.